AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$ABT

Ford Robert B sold $46.2M of ABT

Ford Robert B (CHAIRMAN AND CEO) sold 398,832 shares of ABBOTT LABORATORIES (ABT) at an average of $115.85 ($115.57–$116.19, $46.20M total) across 2 trades on 2026-08-25.

Original reporting
SEC EDGAR · Ford Robert B
Published Aug 27, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The sale reduces insider ownership, potentially weakening confidence among shareholders.

02

Market read

A significant insider sell by the CEO is a material event that can influence short-term price action.

03

What to watch

No 10b5-1 plan; timing may be driven by personal liquidity needs rather than negative outlook.

Relevance 7/10Novelty 8/10Timing: filed 2026-08-27

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Chairman and CEO Robert B. Ford sold 398,832 shares for $46.2M, reducing his stake to 306,461 shares.

Expected impact

Potential short-term downside pressure as market digests the sizable sell.

Evidence & confidence

The transaction size ($46M) is material for a large-cap pharma and the insider is the CEO, making it a notable market-moving event.

Market effects

Sector

May affect perception of Abbott Laboratories' governance and could influence biotech sector sentiment.

Regional

Primarily U.S. market impact; limited regional effect.

Global

Limited to investors tracking large-cap pharma insiders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Executive
    Robert B. Ford

    Chairman and CEO of Abbott Laboratories

  • Company
    Abbott Laboratories

    Global healthcare and diagnostics firm

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

OCT 7
$ABTLow

Whistleblowers Help DOJ Achieve $385 Million Settlement with Abbott Laboratories for Contaminated Infant Formula Sold to Government Programs – RACmonitor

Abbott Laboratories agreed to a $385M settlement with the DOJ for alleged false claims related to contaminated infant formula sold to government programs. The settlement resolves claims that Abbott failed to meet manufacturing standards at its Michigan and Arizona facilities. The company did not admit liability. The settlement includes $348.7M to the federal government and $36.3M to state Medicaid programs. Three whistleblowers will receive $69M for their role in exposing the allegations.

medlearn.com2 min
OCT 7
$ABTLow

Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything

Abbott Laboratories agreed to a $385M settlement to resolve a False Claims Act lawsuit over alleged contamination at its Sturgis, Michigan, and Casa Grande, Arizona, plants. The DOJ and state AGs filed the suit, citing poor conditions and alleged concealment of contamination tests. Abbott denied liability. The 2022 recall caused widespread formula shortages. Whistleblowers will receive $69M.

lawnews.co.uk2 min
OCT 6
MedAI 8/10

Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative?

Abbott Laboratories received FDA approval for upgrades to its CardioMEMS HF System and launched SimpleScreen CRC, a blood-based colorectal cancer screening test. These updates extend Abbott's reach in heart failure monitoring and early cancer detection. Analysts expect 8.8% yearly revenue growth and profit margins rising to 16.0% by 2029, with a consensus earnings forecast of $9.6b by 2029.

simplywall.st3 min